Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-25T05:52:32.710Z Has data issue: false hasContentIssue false
  • English
  • Français

CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE

Published online by Cambridge University Press:  31 July 2017

Chara Kani ,
Vasilios Kourafalos  and
Panagiota Litsa
Chara Kani
Affiliation:
EOPYY, Medicines [email protected]
Vasilios Kourafalos
Affiliation:
EOPYY, Medicines Division
Panagiota Litsa
Affiliation:
EOPYY, Medicines Division
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to describe the current regulatory environment in Greece to evaluate the potential introduction of health technology assessment (HTA) for medicinal products for human use.

Methods: Data sources consist of national legislation on pricing and reimbursement of health technologies to identify the potential need of establishing HTA and its relevant structure.

Results: The pricing procedure regarding medicinal products for human use is based on an external reference pricing mechanism which considers the average of the three lowest Euorpean Union prices. Currently, a formal HTA procedure has not been applied in Greece, and the only prerequisite used for the reimbursement of medicinal products for human use is their inclusion in the Positive Reimbursement List. To restrict pharmaceutical expenditure, a variety of measures—such as clawback mechanisms, rebates, monthly budget caps per physician, generics penetration targeting—have been imposed, aiming mainly to regulate the price level rather than control the introduction of medicinal products for human use in the Greek pharmaceutical market.

Conclusions: Greece has the opportunity to rapidly build capacity, implement, and take advantage of the application of HTA mechanisms by clearly defining the goals, scope, systems, context, stakeholders, and methods that will be involved in the local HTA processes, taking into account the country's established e-prescription system and the recently adapted legislative framework.

Keywords

Health technology assessmentHealth policyGreece
Type
Theme Submissions
Information
International Journal of Technology Assessment in Health Care , Volume 33 , Issue 3: Theme: HTA in Central-Eastern-Southern Europe , 2017 , pp. 396 - 401
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Polyzos, N, Karakolias, S, Dikeos, C, et al. The introduction of Greek Central Health Fund: Has the reform met its goal in the sector of Primary Health Care or is there a new model needed? BMC Health Serv Res. 2014;14:583.Google Scholar
2. Hellenic Statistical Authority. Greece in figures (October - December 2016) [Internet]. 2016. http://www.statistics.gr/documents/20181/1515741/GreeceInFigures_2016Q4_EN.pdf/b6478000-34ca-4ac5-b6e8-a02ed096ba97 (accessed March 5, 2017).Google Scholar
3. Ministerial Decree C5/17229. Revision of the List of medicinal products for severe diseases of paragraph 2 article 12 of Law 3816/2010. Official Gazette 1119 B; 2016 p. 14291-14302.Google Scholar
4. Law 3816/2010. Article 12. Reintroduction of the Positive Reimbursement List and framework rationalization for medicinal products administered to severe diseases. Official Gazette 6A; 2010 p. 23-29.Google Scholar
5. Kolasa, K, Kalo, Z, Zah, V, Dolezal, T. Role of health technology assessment in the process of implementation of the EU Transparency Directive: Relevant experience from Central Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2012;12:283-287.Google Scholar
6. Lopert, R, Ruiz, F, Chalkidou, K. Applying rapid “de-facto” HTA in resource-limited settings: Experience from Romania. Health Policy (New York). 2013;112:202-208.Google Scholar
7. Drummond, MF, Schwartz, JS, Jönsson, B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244-258.Google Scholar
8. Kaló, Z, Gheorghe, A, Huic, M, Csanádi, M, Kristensen, FB. HTA Implementation roadmap in central and eastern European countries. Health Econ. 2016;25 (Suppl 1):179-192.Google Scholar
9. Gulácsi, L, Rotar, AM, Niewada, M, et al. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Heal Econ. 2014;(Suppl 1):S13-S25.Google Scholar
10. Zavras, D, Zavras, AI, Kyriopoulos, I-I, et al. Economic crisis, austerity and unmet healthcare needs: The case of Greece. BMC Health Serv Res. 2016;16:309.Google Scholar
11. Vandoros, S, Hessel, P, Leone, T, Avendano, M. Have health trends worsened in Greece as a result of the financial crisis? A quasi-experimental approach. Eur J Public Health. 2013;23:727-731.Google Scholar
12. Vandoros, S, Stargardt, T. Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy. 2013;109:1-6.CrossRefGoogle ScholarPubMed
13. Fuchs, S, Olberg, B, Panteli, D, Busse, R. Health technology assessment of medical devices in europe: Processes, practices, and methods. Int J Technol Assess Health Care. 2016;27:1-10.Google Scholar
14. Ministerial Decree C5/28408. Pricing Provisions. Official Gazette 1102; 2016 p. 14113-14124.Google Scholar
15. 4336/2015 L. Article 2.5.2.Healthcare. Provisions regarding pensions - Ratification of the Draft Agreement on the Financial Assistance by the European Stability Mechanism (E.S.M) regarding the implementation of the Financing Agreement. Official Gazzette 94A’; 2015 p. 929-1036.Google Scholar
16. Ministerial Decree 70519. Paragraph 3-Rebate provisions. Official Gazette 2243 B’; 2014 p. 27991-28066.Google Scholar
17. Ministerial Decree 62494. Setting prescribing limits for medicinal produtcs. Official Gazette 1920 B’; 2014 p. 24211-24218.Google Scholar
18. Law 4316/2014. Urgent arrangments for the implementation of agreement on fiscal goals and srtuctural reforms and other provisions. Official Gazette 270 A’; 2014 p. 1889-1900.Google Scholar
19. Law 4052/2012. Article 11. Provisions for the implementation of Memorandum of Understanding. Official Gazette 41 A’; 2012 p. 1115-1182.Google Scholar
20. Ministerial Decree C5/63587. Claw back for pharmaceutical expenditure for years 2016, 2017, 2018. Official Gazette 1803 B’; 2015 p. 21279-21280.Google Scholar
21. Law 4208/2013. Article 3. Arrangments and other provisions of Ministry of Health. Official Gazette 252 A’; 2013 p. 4327-4334.Google Scholar
22. Klemp, M, Frønsdal, KB, Facey, K, HTAi Policy Forum. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011;27:77-83.Google Scholar
23. Law 4368/2016. Article 33. Healthcare coverage of unisured and vulnerable social groups. Official Gazette 21 A’; 2016 p. 537-612.Google Scholar
24. Gagnon, M-P, Candas, B, Desmartis, M, et al. Involving patient in the early stages of health technology assessment (HTA): A study protocol. BMC Health Serv Res. 2014;14:1-7.Google Scholar
25. European Commission. Transparent value framework (Platform on access to medicines in Europe - Working Group on Mechanism of coordinated access to orphan medicinal products) [Internet]. 2014. http://ec.europa.eu/DocsRoom/documents/7631?locale=en (accessed October 16, 2016).Google Scholar
26. Marsh, K, IJzerman, M, Thokala, P, et al. Multiple criteria decision analysis for health care decision making–Emerging good practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:125-137.Google Scholar
27. de Labry Lima, AO, Mochon, LG, Martínez, AC, Ruiz, EM, Balbino, JE. Mapping capacity to conduct health technology assessment in Central, Eastern and South-Eastern Europe. Croat Med J. 2016;57:66-70.Google Scholar
28. EUnetHTA Joint Action 2, Work Package 7, Subgroup 3, Heintz, E, Gerber-Grote, A, et al. Is There a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA Partner Countries. Pharmacoeconomics. 2016;34:59-76.Google Scholar